Maybe I saw that. I'm guessing that he isn't going to go anywhere. I think that the shorts will are very likely to brazen it out and move to arguing 1. 'OK but what does MHRA know, whatever, the FDA is still never gonna approve. 2. until the pricing is decided and made public 'OK but the UK health service isn't going to pay enough to give any decent margins to NWBO' aka 'NICE will not pay for it at anywhere near the ask' 3. They will never get much penetration into the GBM patient population. 4. any other half-baked pasta arguments they can try to throw against the wall.
In other words, the FUD and MM pressures against the stock will continue (UNLESS wrt to the MM the suit goes to trial and the MM get forced or get wise enough under the legal threat to pull back). This time (i.e. approval by MHRA) will leave a mark on the shorts but we've seen them successful in pushing back like crazy against any gain. To be guaranteed that woh't happen again we need to have more good sized investors realize this Muricidel is going to become the SOC for GBM internationally fairly quickly, and as has been said by those who know more than I do, we need to get onto a better exchange where the larger inward money flows will be enabled. I'm not hugely confident that MHRA approval is going to be all we need for the stock to rebase up at a few bucks or better. It still seems more likely than not that the shorts will be die-hard until completely forced out. JMHO, I have no idea and will be waiting to see what happens.
News 
Market Data 
Discover 
AI
